CD19 positive

News alerts, weekly reports and conference planners

Entrez ID:

930

Related biomarkers:

‹

›

CD19 positive	Acute Lymphocytic Leukemia	CD19 positive	Acute Lymphocytic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	CTX110 Sensitive: B - Late Trials CTX110 Sensitive : B	CTX110 Sensitive: B - Late Trials CTX110 Sensitive : B
CD19 positive	Non-Hodgkin’s Lymphoma	CD19 positive	Non-Hodgkin’s Lymphoma	CTX110 Sensitive: B - Late Trials CTX110 Sensitive : B	CTX110 Sensitive: B - Late Trials CTX110 Sensitive : B
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	CAR-T immunotherapy Sensitive: C3 – Early Trials CAR-T immunotherapy Sensitive : C3	CAR-T immunotherapy Sensitive: C3 – Early Trials CAR-T immunotherapy Sensitive : C3
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	YT-19 Sensitive: C3 – Early Trials YT-19 Sensitive : C3	YT-19 Sensitive: C3 – Early Trials YT-19 Sensitive : C3
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	tisagenlecleucel-T Sensitive: C3 – Early Trials tisagenlecleucel-T Sensitive : C3	tisagenlecleucel-T Sensitive: C3 – Early Trials tisagenlecleucel-T Sensitive : C3
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	PBCAR0191 Sensitive: C3 – Early Trials PBCAR0191 Sensitive : C3	PBCAR0191 Sensitive: C3 – Early Trials PBCAR0191 Sensitive : C3
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
CD19 positive	Non-Hodgkin’s Lymphoma	CD19 positive	Non-Hodgkin’s Lymphoma	tisagenlecleucel-T Sensitive: C3 – Early Trials tisagenlecleucel-T Sensitive : C3	tisagenlecleucel-T Sensitive: C3 – Early Trials tisagenlecleucel-T Sensitive : C3
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	pCAR-19B Sensitive: C3 – Early Trials pCAR-19B Sensitive : C3	pCAR-19B Sensitive: C3 – Early Trials pCAR-19B Sensitive : C3
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	nivolumab + ipilimumab + blinatumomab Sensitive: C3 – Early Trials nivolumab + ipilimumab + blinatumomab Sensitive : C3	nivolumab + ipilimumab + blinatumomab Sensitive: C3 – Early Trials nivolumab + ipilimumab + blinatumomab Sensitive : C3
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	nivolumab + blinatumomab Sensitive: C3 – Early Trials nivolumab + blinatumomab Sensitive : C3	nivolumab + blinatumomab Sensitive: C3 – Early Trials nivolumab + blinatumomab Sensitive : C3
CD19 positive	Follicular Lymphoma	CD19 positive	Follicular Lymphoma	acalabrutinib + axicabtagene ciloleucel Sensitive: C3 – Early Trials acalabrutinib + axicabtagene ciloleucel Sensitive : C3	acalabrutinib + axicabtagene ciloleucel Sensitive: C3 – Early Trials acalabrutinib + axicabtagene ciloleucel Sensitive : C3
CD19 positive	Diffuse Large B Cell Lymphoma	CD19 positive	Diffuse Large B Cell Lymphoma	acalabrutinib + axicabtagene ciloleucel Sensitive: C3 – Early Trials acalabrutinib + axicabtagene ciloleucel Sensitive : C3	acalabrutinib + axicabtagene ciloleucel Sensitive: C3 – Early Trials acalabrutinib + axicabtagene ciloleucel Sensitive : C3
CD19 positive	Small Lymphocytic Lymphoma	CD19 positive	Small Lymphocytic Lymphoma	T-lymphocyte cell therapy Sensitive: C4 – Case Studies T-lymphocyte cell therapy Sensitive : C4	T-lymphocyte cell therapy Sensitive: C4 – Case Studies T-lymphocyte cell therapy Sensitive : C4
CD19 positive	Chronic Lymphocytic Leukemia	CD19 positive	Chronic Lymphocytic Leukemia	T-lymphocyte cell therapy Sensitive: C4 – Case Studies T-lymphocyte cell therapy Sensitive : C4	T-lymphocyte cell therapy Sensitive: C4 – Case Studies T-lymphocyte cell therapy Sensitive : C4
CD19 positive	Follicular Lymphoma	CD19 positive	Follicular Lymphoma	A-319 Sensitive: C4 – Case Studies A-319 Sensitive : C4	A-319 Sensitive: C4 – Case Studies A-319 Sensitive : C4
CD19 positive	Diffuse Large B Cell Lymphoma	CD19 positive	Diffuse Large B Cell Lymphoma	A-319 Sensitive: C4 – Case Studies A-319 Sensitive : C4	A-319 Sensitive: C4 – Case Studies A-319 Sensitive : C4
CD19 positive	Acute Lymphocytic Leukemia	CD19 positive	Acute Lymphocytic Leukemia	FT596 Sensitive: D – Preclinical FT596 Sensitive : D	FT596 Sensitive: D – Preclinical FT596 Sensitive : D
CD19 positive	Non-Hodgkin’s Lymphoma	CD19 positive	Non-Hodgkin’s Lymphoma	ISIKOK-19 Sensitive: D – Preclinical ISIKOK-19 Sensitive : D	ISIKOK-19 Sensitive: D – Preclinical ISIKOK-19 Sensitive : D
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	ISIKOK-19 Sensitive: D – Preclinical ISIKOK-19 Sensitive : D	ISIKOK-19 Sensitive: D – Preclinical ISIKOK-19 Sensitive : D
CD19 positive	Mantle Cell Lymphoma	CD19 positive	Mantle Cell Lymphoma	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D	T-lymphocyte cell therapy Sensitive: D – Preclinical T-lymphocyte cell therapy Sensitive : D
CD19 positive	Non-Hodgkin’s Lymphoma	CD19 positive	Non-Hodgkin’s Lymphoma	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D

CD19 positive

Associations